Hypophosphatasia clinical trials

Explore recruiting hypophosphatasia clinical trials.

Recruiting hypophosphatasia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypophosphatasia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 years of age) and Adult Participants with Hypophosphatasia Who Have Not Previously Been Treated with Asfotase Alfa (Hickory)

Poland, Austria, Germany, Belgium, Italy, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomised, Placebo-Controlled, Double-Blind, Single-Ascending Dose and Multiple-Ascending Dose First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered ALE1 With or Without Food in Healthy Adult Participants and Adult Patients With Hypophosphatasia

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Open-Label Pilot Trial to Evaluate the Effects of Ilofotase Alfa on Biomarkers in Adult Patients with Hypophosphatasia

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

France

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric Participants (2 to < 12 years of age) with Hypophosphatasia (HPP) Previously Treated with Asfotase Alfa (Chestnut)

Italy, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 Versus Placebo Administered Subcutaneously in Pediatric (2 to < 12 years of age) Participants with Hypophosphatasia Who Have Not Received Previous Treatment with Asfotase Alfa

Italy, Belgium, Spain, France, Poland, Sweden +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hypophosphatasia trials by city

Hypophosphatasia in Toronto Hypophosphatasia in Vancouver Hypophosphatasia in Montreal Hypophosphatasia in Calgary Hypophosphatasia in Edmonton Hypophosphatasia in Ottawa Hypophosphatasia in Winnipeg Hypophosphatasia in Quebec City Hypophosphatasia in Hamilton Hypophosphatasia in Kitchener Hypophosphatasia in London Hypophosphatasia in Halifax Hypophosphatasia in New York Hypophosphatasia in Los Angeles Hypophosphatasia in Chicago Hypophosphatasia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease